Science & Enterprise subscription

Follow us on Twitter

  • A new venture investment company is funding start-ups at their earliest stages, with a goal of increasing support f… https://t.co/mM44gsVcT9
    about 16 hours ago
  • New post on Science and Enterprise: Early Venture Investors Aim for Diverse Entrepreneurs https://t.co/y9tdzGJ9rP #Science #Business
    about 16 hours ago
  • Fascinating hypothesis. We wrote about this team's work in nanomedicine for crossing blood-brain barrier in October… https://t.co/ud8TGIrXt7
    about 18 hours ago
  • The Food and Drug Administration issued its standards that developers need to meet in evidence submitted for review… https://t.co/0G93MkzRwL
    about 1 day ago
  • New post on Science and Enterprise: FDA Sets Review Criteria for Covid-19 Vaccines https://t.co/87eIr3uU3t #Science #Business
    about 1 day ago

Please share Science & Enterprise

FDA Fast-Track Granted to Cancer Therapy Side-Effects Drug

Chemotherapy (National Institutes of Health)

(National Institutes of Health)

BioAlliance Pharma SA in Paris says its drug candidate to treat inflammation of the mucus membranes in the mouth, resulting from chemo- or radiation therapy to treat cancer, received fast-track status from the U.S. Food and Drug Administration. Validive, the drug’s brand name, is designed for patients with head and neck cancers.

Oral mucositis is an adverse effect of chemo- and radiation therapy, which can become severe and take up to eight weeks to heal, depending on the length of time exposed to radiation. The condition can result in pain, bleeding, or infection.

Valdive works by stimulating the alpha-2 adrenergic receptors that decrease the release of proteins encouraging inflammation of mucus membranes in the mouth. The company says its technology also increases the concentration of Valdive’s active ingredients in mucus and saliva.

BioAlliance Pharma says Valdive is currently in intermediate-stage clinical trials, with 180 head and neck cancer patients in the U.S. and Europe who received chemotherapy or radiation therapy, and who suffer from oral mucositis. In the trial, the drug is being tested against a placebo.

FDA’s fast track process expedites the review of drugs designed to address unmet medical needs. Fast track status provides new drug developers with more frequent meetings and correspondence with FDA officials. The company says Valdive also received orphan drug designation in Europe.

Read more:

*     *     *

Please share Science & Enterprise ...

Comments are closed.